As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.
18 Analysts have issued a Ocular Therapeutix Inc forecast:
18 Analysts have issued a Ocular Therapeutix Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | 57 57 |
7%
7%
|
|
Gross Profit | 51 51 |
9%
9%
|
|
EBITDA | -224 -224 |
80%
80%
|
EBIT (Operating Income) EBIT | -228 -228 |
78%
78%
|
Net Profit | -217 -217 |
57%
57%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Head office | United States |
CEO | Pravin Dugel |
Employees | 274 |
Founded | 2006 |
Website | www.ocutx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.